This is a routine internal role consolidation with no financial or operational implications. The recent DEFA14A proxy solicitation (April 29) suggests board-level activity, but this filing is unrelated. No trading action warranted.
Price Chart
Executive Summary
C4 Therapeutics disclosed the departure of Chief Accounting Officer Mark Mossler, effective May 15, 2026, with no disagreement cited. CFO Kendra R. Adams has been appointed as the new principal accounting officer without additional compensation. This is a routine internal role consolidation, not a red-flag departure.
Key Facts
- Mark Mossler will cease serving as Chief Accounting Officer effective May 15, 2026.
- Departure is explicitly stated as not due to any disagreement with the company or board on financial reporting, operations, policies, or practices.
- CFO Kendra R. Adams has been designated as the new principal accounting officer, effective May 15, 2026.
- Adams will receive no additional compensation for assuming the principal accounting officer role.
- A DEFA14A proxy filing from April 29, 2026 (16 days prior) indicates recent contested election or solicitation activity.
Financial Impact
No financial impact. Role consolidation with no compensation change.
Risk Factors
- No material risks identified from this filing alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-035542 |
| Document: 0001628280-26-035542-index-headers.html | 0001628280-26-035542 |
| Document: 0001628280-26-035542-index.html | 0001628280-26-035542 |
| Document: 0001628280-26-035542.txt | 0001628280-26-035542 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 6w ago | 144 | $4.27 $4.10 | ▼ −3.87% | ▼ −2.68% | $2.95 (−30.83%) |
Aug 14, 2026 6w ago | Institutional Cluster | $4.27 $4.10 | ▼ −3.87% | ▼ −2.68% | $2.95 (−30.83%) |
Aug 11, 2026 7w ago | 8-K | $3.62 $4.18 | ▲ +15.47% | ▲ +15.87% | $2.95 (−18.51%) |
Jun 11, 2026 16w ago | Press Release | $3.87 $3.92 | ▲ +1.29% | ▲ +0.86% | $2.95 (−23.77%) |
May 15, 2026 20w ago | 8-K | $3.22 $3.49 | ▲ +8.39% | ▲ +6.77% | $2.95 (−8.39%) |
May 12, 2026 20w ago | 8-K | $3.17 $3.22 | ▲ +1.58% | ▲ +1.50% | $2.95 (−6.94%) |
May 12, 2026 20w ago | Press Release | $3.17 $3.22 | ▲ +1.58% | ▲ +1.50% | $2.95 (−6.94%) |
Apr 9, 2026 25w ago | 8-K | $2.83 $2.90 | ▲ +2.47% | ▼ −0.71% | $2.95 (+4.24%) |
Apr 9, 2026 25w ago | Press Release | $2.83 $2.90 | ▲ +2.47% | ▼ −0.71% | $2.95 (+4.24%) |
Mar 25, 2026 27w ago | Press Release | $2.69 $2.70 | ▲ +0.37% | ▲ +0.62% | $2.95 (+9.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access